Lymphoplasmacytic Lymphoma Clinical Trial
Official title:
Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
The purpose of this study is to determine the percentage of people who can attain remission and the length of time such responses to therapy are sustained, as well as the side effects that might result from rituximab and thalidomide in people with lymphoplasmacytic lymphoma.
- Patients will receive thalidomide(200mg) orally once daily for two weeks. If after two
weeks of thalidomide, the patient is doing well the dose of thalidomide will increase
(400mg) and they will remain on it for up to 50 additional weeks. The length of time a
patient is on thalidomide will depend upon how they are responding to therapy.
- During the second week of the study patients will also begin receiving rituximab
intravenously once weekly for 4 weeks, which may then be repeated 8 weeks later
depending upon the response.
- A determination of how the patient is responding will be made based on testing
conducted at 12 weeks. This testing includes blood tests and possibly a bone marrow
biopsy. If it is determined that the disease is not progressing, patients will begin a
second phase of treatment which includes 4 additional weekly infusions of rituximab and
the continuation of oral thalidomide.
- If it is determined at the 12-week evaluation, or at any time thereafter, that the
disease has progressed (by studying serum immunoglobulin M (IgM) levels, bone marrow
involvement, tumor cells, and/or development of new signs and symptoms) then the
patient will be removed from the study.
- Periodic examinations and tests will be done to determine how the patient is doing,
what response and side effects (if any) the patient may be having from the study drugs.
If patient is responding to therapy then they will remain on this study and followed
for a period of two years.
- Bone marrow biopsies and aspirations will be obtained at 3-6 month intervals extending
for 2 years following the last treatment.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04883437 -
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
|
Phase 2 | |
Recruiting |
NCT04545762 -
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT03133221 -
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT03019666 -
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
|
Phase 1 | |
Recruiting |
NCT03335098 -
Study of VTD in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Active, not recruiting |
NCT00719888 -
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
|
Phase 2 | |
Recruiting |
NCT00923507 -
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
|
||
Completed |
NCT01314014 -
Imexon for Relapsed Follicular and Aggressive Lymphomas
|
Phase 2 | |
Recruiting |
NCT04799275 -
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02339922 -
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
|
Phase 2 | |
Terminated |
NCT03601819 -
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
|
Phase 1 | |
Active, not recruiting |
NCT02722668 -
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
|
Phase 2 | |
Completed |
NCT02661035 -
Allo HSCT Using RIC for Hematological Diseases
|
Phase 2 | |
Recruiting |
NCT03314974 -
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
|
Phase 2 | |
Recruiting |
NCT06340737 -
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
|
Phase 1 | |
Completed |
NCT00142181 -
Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT01282424 -
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
|
Phase 2 | |
Completed |
NCT04858568 -
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
|
||
Completed |
NCT00644189 -
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00566332 -
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
|
Phase 3 |